scholarly journals Comparative study between serum level of hepatocyte growth factor and CA-125 in patients with suspicious malignant adnexal masses

2016 ◽  
Vol 6 (1) ◽  
pp. 38
Author(s):  
Ziad Mansour Ahmed ◽  
Helmy Helmy Abdel Satar ◽  
Moyassar Ahmed Zaki ◽  
Hassan Mansour Hassan
Keyword(s):  
Ovarian Cancer ◽  
Growth Factor ◽  
Serum Level ◽  
Hepatocyte Growth Factor ◽  
Serum Levels ◽  
Ca 125 ◽  
Control Group ◽  
Ovarian Carcinomas ◽  
Adnexal Masses ◽  
Hepatocyte Growth

Background: Hepatocyte growth factor has been described to be increased in different cancers. The aim of the present study is to evaluate as a screening marker the‏ serum level of Hepatocyte growth factor among suspicious adnexal masses as compared to serum levels of CA125.Methods: The present study included 80 female patients who are admitted to the Gynecology unit in Elshatby Maternity University Hospital divided into two groups. Forty patients with benign gynecological conditions (control group) and 40 patients with suspicious malignant adnexal masses (cases group). Preoperative blood samples were withdrawn from all patients of both cases and control group to assess the level of serum hepatocyte growth factor (HGF) and serum cancer antigen 125 (CA 125). Both were quantified using ELISA technique.Results: Out of the 40 cases with suspicious malignant adnexal masses, 35 had ovarian cancer while five only were borderline. Patients with ovarian carcinomas had significantly higher preoperative HGF and CA 125 serum levels than patients with borderline pathology. Patients with borderline tumors had a significantly higher serum HGF and CA 125 levels than patients with benign gynecological conditions in control group.Conclusions: HGF in serum was elevated in 71% of patients with suspicious malignant adnexal masses proved to be ovarian cancer by histopathology using a quantitative ELISA. HGF can be used as a screening tool for ovarian cancer.

scholarly journals Decreased Serum Hepatocyte Growth Factor (HGF) in Autistic Children with severe Gastrointestinal Disease

2009 ◽  
Vol 4 ◽  
pp. BMI.S3656 ◽  
Author(s):  
A.J. Russo ◽  
A. Krigsman ◽  
B. Jepson ◽  
Andrew Wakefield
Keyword(s):  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Gastrointestinal Disease ◽  
Serum Levels ◽  
Autistic Children ◽  
Functional Connection ◽  
Disease Symptoms ◽  
Lymphoid Nodular Hyperplasia ◽  
Lymphoid Nodules ◽  
Hepatocyte Growth

Aim To assess serum Hepatocyte Growth Factor (HGF) levels in autistic children with severe gastrointestinal (GI) disease and to test the hypothesis that there is a relationship between GI pathology and HGF concentration. Subjects and Methods Serum from 29 autistic children with chronic digestive disease (symptoms for a minimum of 6–12 months), most with ileo-colonic lymphoid nodular hyperplasia (LNH—markedly enlarged lymphoid nodules) and inflammation of the colorectum, small bowel and/or stomach), and 31 controls (11 age matched autistic children with no GI disease, 11 age matched non autistic children without GI disease and 9 age matched non autistic children with GI disease) were tested for HGF using ELISAs. HGF concentration of autistic children with GI disease was compared to GI disease severity. Results Autistic children with GI disease had significantly lower serum levels of HGF compared to controls (autistic without GI disease; p = 0.0005, non autistic with no GI disease; p = 0.0001, and non autistic with GI disease; p = 0.001). Collectively, all autistic children had significantly lower HGF levels when compared to non autistic children (p < 0.0001). We did not find any relationship between severity of GI disease and HGF concentration in autistic children with GI disease. Discussion These results suggest an association between HGF serum levels and the presence of GI disease in autistic children and explain a potential functional connection between the Met gene and autism. The concentration of serum HGF may be a useful biomarker for autistic children, especially those with severe GI disease.

Induction of liver growth in normal mice by infusion of hepatocyte growth factor/scatter factor

1995 ◽  
Vol 268 (2) ◽  
pp. G380-G386 ◽  
Author(s):  
F. Roos ◽  
A. M. Ryan ◽  
S. M. Chamow ◽  
G. L. Bennett ◽  
R. H. Schwall
Keyword(s):  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Dextran Sulfate ◽  
Plasma Concentrations ◽  
Elevated Serum ◽  
Serum Levels ◽  
Serum Biochemistry ◽  
Scatter Factor ◽  
Liver Growth ◽  
Hepatocyte Growth

Hepatocyte growth factor/scatter factor (HGF/SF) is a potent stimulator of DNA synthesis in a variety of epithelial cells, including hepatocytes, and has been implicated in liver regeneration. We show here that combining dextran sulfate with HGF/SF markedly increases the plasma concentrations of HGF/SF that are achieved during intraperitoneal infusion. Three days of administration of HGF/SF by this mechanism caused a dose-dependent increase in liver wet weight. Mitotic figures were rarely observed in control livers but were abundant in livers exposed to HGF/SF, and liver DNA content was elevated. Serum levels of triglycerides, cholesterol, total protein, and albumin were also dose dependently increased, whereas alkaline phosphatase was reduced. From these data we conclude 1) that combining HGF/SF with dextran sulfate provides a novel method for delivering HGF/SF in a continuous manner, 2) that HGF/SF can induce liver growth in an intact animal, and 3) that HGF/SF-induced liver enlargement is associated with changes in serum biochemistry.

scholarly journals Humanized Anti-hepatocyte Growth Factor Monoclonal Antibody (YYB-101) Inhibits Ovarian Cancer Progression

2019 ◽  
Vol 9 ◽  
Author(s):  
Hyun Jung Kim ◽  
Sukmook Lee ◽  
Yong-Seok Oh ◽  
Ha Kyun Chang ◽  
Young Sang Kim ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Monoclonal Antibody ◽  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Cancer Progression ◽  
Hepatocyte Growth

scholarly journals Clinical Significance of Hepatocyte Growth Factor and Transforming Growth Factor-Beta-1 Levels in Assessing Disease Activity in Inflammatory Bowel Disease

2020 ◽  
Vol 2020 ◽  
pp. 1-5
Author(s):  
Rania Naguib ◽  
Wafaa Mohamed El-Shikh
Keyword(s):  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Disease Activity ◽  
Transforming Growth Factor Beta ◽  
Transforming Growth Factor ◽  
Inflammatory Responses ◽  
Control Group ◽  
Inflammatory Bowel ◽  
Growth Factor Beta ◽  
Hepatocyte Growth

Background. Transforming growth factor-beta (TGF-β) and hepatocyte growth factor (HGF) are inflammatory cytokines which function as key regulators of immunological homeostasis and inflammatory responses. They have been linked to inflammatory bowel diseases (IBD). In this study, we aim to assess the levels of TGF-β and HGF and other inflammatory markers in patients with IBD and correlate them with the disease activity. Study Design. A cross-sectional study involving 100 patients with ulcerative colitis (UC) and 100 patients with Crohn’s disease (CD) and 50 control subjects. TGF-β and HGF levels were measured and correlated with disease activity. Results and Conclusion. Serum levels of TGF-β and HGF were significantly higher in IBD patients compared with the control group. In the UC group, the levels of HGF and TGF-β were significantly higher than in the CD group. Levels of TGF-β and HGF correlate with the activity of IBD.

Serum Levels of Hepatocyte Growth Factor/Scatter Factor in Patients with Liver Metastases from Breast Cancer

Tumor Biology ◽  
2007 ◽  
Vol 28 (1) ◽  
pp. 36-44 ◽  
Author(s):  
Michael H.R. Eichbaum ◽  
Thomas M. de Rossi ◽  
Sepp Kaul ◽  
Thomas Bruckner ◽  
Andreas Schneeweiss ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Liver Metastases ◽  
Serum Levels ◽  
Scatter Factor ◽  
Hepatocyte Growth

Comparison of HGF (hepatocyte growth factor) levels of epithelial ovarian cancer cyst fluids with benign ovarian cysts

2003 ◽  
Vol 13 (6) ◽  
pp. 771-775 ◽  
Author(s):  
C. Baykal ◽  
E. Demirtas ◽  
A. Al ◽  
A. Ayhan ◽  
K. Yuce ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Growth Factor ◽  
Epithelial Cells ◽  
Hepatocyte Growth Factor ◽  
Epithelial Ovarian Cancer ◽  
Gynecologic Oncology ◽  
Maternity Hospital ◽  
Ovarian Cysts ◽  
Hepatocyte Growth ◽  
Cyst Fluids

Hepatocyte growth factor (HGF) is known to take a role in oncogenesis and tumoral behavior of the tumors of the organs that contain both mesenchymal and epithelial cells. This study compares HGF levels in cyst fluids of epithelial ovarian cancer and benign ovarian cysts to look for the role of HGF in ovarian carcinogenesis. Twenty-four consecutive patients with ovarian cancer and 34 with benign ovarian cysts were recruited prospectively at the Gynecologic Oncology Departments of SSK Ankara Maternity Hospital and Hacettepe University School of Medicine between 2001 and 2002. Cyst fluids were collected during primary staging in cancer patients and during laparatomy for benign patients. HGF levels were measured by ELISA method. Median HGF levels of the benign ovarian cysts and epithelial ovarian tumoral fluids were found to be 3822 pg/ml (85–15,253 pg/ml) and 12,962 pg/ml (4136–16,025 pg/ml), respectively. Malignant cyst fluids have higher HGF levels when compared with benign ovarian cysts (P < 0.01). This finding suggests that HGF may take a paracrine role in oncogenic differentiation and tumoral development of epithelial ovarian cancers. Mechanisms that take a role in HGF secretion and the responses of neighboring epithelial cells to HGF during tumoral development need to be investigated.

scholarly journals Decreased Serum Hepatocyte Growth Factor (HGF) in Individuals with Depression Correlates with Severity of Disease

2010 ◽  
Vol 5 ◽  
pp. BMI.S5183 ◽  
Author(s):  
A.J. Russo
Keyword(s):  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Disease Severity ◽  
Serum Levels ◽  
Lower Serum ◽  
Severity Of Disease ◽  
Clinically Depressed ◽  
Severity Of Depression ◽  
Predictive Strength ◽  
Hepatocyte Growth

Aim To assess serum Hepatocyte Growth Factor (HGF) levels in individuals with depression and to test the hypothesis that there is a relationship between severity of depression and HGF concentration. Subjects and methods Serum from 26 clinically depressed individuals and 19 controls were tested for serum HGF using ELISAs. Correlation was established between HGF concentration and disease severity. Results Depressed individuals had significantly lower serum levels of HGF compared to controls ( P < 0.0001). HGF concentration correlated with overall depressive behavior ( P = 0.03) and specifically depression ( P = 0.02), but not anxiety ( P = 0.36). Discussion These results suggest an association between HGF serum levels and clinically depressed individuals and demonstrate a correlation between severity of depression and HGF levels. Further studies of the predictive strength of HGF as a biomarker for depression may be warranted.

Sign in / Sign up

Export Citation Format

Share Document